Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + epirubicin + gemcitabine + vinorelbine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of docetaxel (a taxane), epirubicin (an anthracycline), gemcitabine (a nucleoside antimetabolite), and vinorelbine (a vinca alkaloid). This combination has been studied in various permutations for the treatment of metastatic breast cancer, with particular attention to the sequence of drug administration which can affect both efficacy and toxicity profiles.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on docetaxel + epirubicin + gemcitabine + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + epirubicin + gemcitabine + vinorelbine.